Ikonisys
1999
FOUNDED
PRIVATE
STATUS
51-60
EMPLOYEES
Later Stage VC
LATEST DEAL TYPE
$1.44M
LATEST DEAL AMOUNT
14
INVESTORS
Description
Developer of diagnostic tests designed to transform diagnostic medicine through early, accurate and non-invasive disease detection. The company's diagnostic tests detect a single cell and identify its molecular signals, enabling large and regional reference labs, hospitals, research institutions and practice groups to reduce the risk of human error, lower costs, and expand test volume capacity.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Primary Office
- 5 Science Park
- New Haven, CT 06511
- United States
+1 (203) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ikonisys’s full profile, request a free trial.
Ikonisys Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 20-Jul-2012 | $1.44M | 000.00 | Completed | Generating Revenue | |
| 7. Later Stage VC | 03-Aug-2010 | 00.00 | 0000 | Completed | Generating Revenue | |
| 6. Grant | 31-Dec-2009 | 00000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series E) | 17-Oct-2007 | 0000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 4. Later Stage VC (Series D) | 08-Mar-2006 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series C) | 11-Dec-2003 | 00.000 | 00.000 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series B) | Completed | Startup | ||||
| 1. Early Stage VC (Series A) | Completed | Startup |
Ikonisys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series D | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 | |
| Series C | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series B2 | 000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series B1 | 000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series B | 125,000 | $0.010000 | $4 | $4 | 1x | $4 | 0.18% | |
| Series A | 1,100,000 | $0.010000 | $1.81 | $1.81 | 1x | $1.81 | 1.61% |
Ikonisys Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Qualifying Therapeutic Discovery Project | Government | Minority | 000 0000 | 000000 0 | ||
| Everfin | Corporation | Minority | 000 0000 | 000000 0 | ||
| Goldman Sachs Merchant Banking Division | Merchant Banking Firm | Minority | 000 0000 | 000000 0 | ||
| Investors Group | Other | Minority | 000 0000 | 000000 0 | ||
| Palisade Capital Management | Asset Manager | Minority | 000 0000 | 000000 0 |
Ikonisys Executive Team (14)
7 Former Executives
You’re viewing 5 of 14 executives. Get the full list »Ikonisys Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Christopher Dawe | Self | Board Member | 000 0000 | |
| Fulvio Bracco | Self | Board Member | 000 0000 | |
| Marco Prete | Self | Board Member | 000 0000 | |
| Mario Mauri | Self | Board Member | 000 0000 | |
| Pramod Srivastava | Ikonisys | Co-Founder, Board Member & Senior Advisor to the Board | 000 0000 |
2 Former Board Members
You’re viewing 5 of 12 board members. Get the full list »